FDC Limited — Updates, 27-05-2026: Press Release
27-05-2026 | 03:38 pm
27-05-2026 | 03:38 pm
FDC's Q4 FY26 revenue rose 18.9% to Rs. 585 Cr, with PAT surging 167.4% to Rs. 103 Cr. Export Formulations grew 99.3%, driven by a strong US business (+283.1%). EBITDA margin expanded to 18.2%. The company also received US FDA approval for Fluconazole Tablets.
No comments yet. Be the first to comment!
